EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Clinical trials for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against aggressive lung cancer
Disease control OngoingThis study tests a new treatment combination for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment yet. It combines a PARP inhibitor (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy (carboplatin and etoposide), and radiati…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise in halting aggressive lung cancer
Disease control OngoingThis study tests whether adding talazoparib to atezolizumab helps control extensive-stage small cell lung cancer better than atezolizumab alone. About 100 adults with a specific genetic marker (SLFN11-positive) are participating. The goal is to see if the combination slows cancer…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for lung cancer patients: experimental combo targets hard-to-treat tumors
Disease control OngoingThis early-phase trial tests a three-drug combination (tazemetostat, topotecan, and pembrolizumab) in adults with small cell lung cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors. About…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo aims to outsmart Chemo-Resistant lung cancer
Disease control OngoingThis study tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combo or topotecan alone. The goal is to see if blocking the…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo aims to boost chemo for tough lung cancer
Disease control OngoingThis early-phase trial tests a new drug called LB-100 combined with standard chemotherapy and immunotherapy for people with untreated extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps shrink tumors. Only 3 participants we…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Triple drug cocktail shows promise for tough lung cancer
Disease control OngoingThis study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps keep the cancer from growing longer than …
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:24 UTC